ETNB
$4.35
89Bio
$.27
6.62%
ETNB
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($1.01)
Revenue:  N/A
Thursday
Nov 10
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ETNB reports earnings?
Beat
Meet
Miss

Where is ETNB's stock price going from here?
Up
Flat
Down
Stock chart of ETNB
Analysts
Summary of analysts' recommendations for ETNB
Score
Grade
Pivots
Resistance
$5.93
$5.52
$4.93

$4.52

Support
$3.93
$3.52
$2.93
Tweet
Growth
Description
89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.